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Aicardi-Goutières syndrome (AGS), Systemic Lupus 
Erythematosus (SLE), Familial Chilblain Lupus (FCL) and 
Retinal Vasculopathy and Cerebral Leukodystrophy (RVCL) {a 
new term encompassing three independently described condi-
tions with a common etiology—Cerebroretinal Vasculopathy 
(CRV), Hereditary Vascular Retinopathy (HVR) and Hereditary 
Endotheliopathy, Retinopathy and Nephropathy (HERNS)}—
have previously been regarded as distinct entities. However, 
recent genetic analysis has demonstrated that each of these 
diseases maps to chromosome 3p21 and can be caused by muta-
tions in TREX1, the major human 3'–5' exonuclease. In this 
review, we discuss the putative functions of TREX1 in relation-
ship to the clinical, genetic and functional characteristics of each 
of these conditions.
Introduction
Recently, mutations in the ubiquitously expressed human 3'–5' 
exonuclease TREX1 (DNase III) have been linked to four apparently 
independent diseases. In the case of Cerebroretinal Vasculopathy 
(CRV), Hereditary Endotheliopathy, Retinopathy and Nephropathy 
(HERNS) and Hereditary Vascular Retinopathy (HVR), a common 
etiology was first suspected based on clinical similarities and further 
supported when all showed evidence of linkage to a single locus on 
chromosome 3p21.1 We now know that these diseases consolidate 
to a single autosomal dominant inherited entity named Retinal 
Vasculopathy and Cerebral Leukodystrophy (RVCL) in which there 
are mutations affecting the carboxyl-terminus of TREX1.2 The other 
three diseases, Aicardi-Goutières syndrome (AGS), Systemic Lupus 
Erythematosus (SLE) and Familial Chilblain Lupus (FCL), share 
some clinical similarity but appear to be distinct clinical conditions. 
AGS, a severe, usually lethal disease, resembling an intrauterine viral 
infection has been associated with recessive mutations in TREX1 that 
impair its exonuclease activity.3 FCL is a rare, inherited form of lupus 
with prominent skin manifestations in which autosomal dominant 
mutations in TREX1 that decrease exonuclease activity have been 
described.4,5 Mutations in TREX1 have also been identified in ~3% 
of patients with SLE, a complex disease with diverse, systemic mani-
festations predominantly affecting women of child-bearing age.6 
The goal of this review is to collate the existing information on these 
genetically related diseases with an emphasis on how the mutations 
in TREX1 lead to the disease state.
Nucleases Role in Cell Biology
Deoxyribonucleases (DNA nucleases) are essential to maintain 
genome stability and are involved in processes such as DNA repli-
cation, repair and recombination.7 These enzymes can be divided 
into two classes: endonucleases that hydrolyse the deoxyribose phos-
phodiester backbone within the DNA strand and exonucleases that 
hydrolyse the phosphodiester bonds at the DNA ends. Nucleases 
have selective affinity for single-stranded (ss) or double-stranded (ds) 
DNA. They differ in their mode of action (5'–3' or 3'–5' direction) 
and their main reaction products (5' mono- or dinucleotides and 3' 
mononucleotides).8
DNA replication during mitosis follows a complex sequence of 
events in which polymerases are responsible for the accurate duplica-
tion of the parental chromosomes. In mammalian cells, the estimated 
spontaneous mutation rate is 10-10–10-12 per cell division.9 This 
is, however, orders of magnitudes lower than the mutation rate of 
DNA polymerases such as Pol α and Pol β (10-4–10-5).10 They are 
not accurate enough to replicate our 3 billion base pair genome 
without deleterious consequences. Such a high mutation rate would 
be incompatible with life and is why some DNA polymerases (e.g., 
Pols γ, δ and ε) contain additional 3'–5' exonuclease activity. This 
“intrinsic” proofreading activity enables the polymerases to enhance 
the accuracy of DNA synthesis by removing incorrectly incorporated 
nucleotides before the replication process is reinitiated.
A second class of exonucleases is considered autonomous. These 
enzymes can hydrolyse their target sequences independently and 
may also assist DNA polymerases lacking this activity (e.g., Pol 
α) to increase their fidelity under normal conditions or in cases 
of genotoxic cell stress.9 TREX1 is the most abundant DNA 3'–5' 
exonuclease in mammalian cells.8,11
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TREX1 Genetics and Structure
TREX1 (former DNase III, Three prime Repair EXonuclease) 
was identified in 1999 by Hoss et al.12 and Mazur and Perrino.13 
The gene for TREX1 consists of a single exon and encodes a protein 
of 314 amino acids. Sequence homology places TREX1 in the DnaQ 
3'–5' exonuclease family.14-16 The characteristic features of this 
family of exonucleases are three conserved sequence motifs, Exo I, 
Exo II and Exo III, which form the active site of the enzyme14-16 
(Fig. 1). Recent crystal structures of murine Trex1 with DNA17 
demonstrate a dimer with the active sites on opposing surfaces, 
allowing the potential for concurrent interaction with two 3' DNA 
ends. These structures demonstrate close similarity with another 
DnaQ 3'–5' exonuclease, the Escherichia coli DNA polymerase I. 
In addition to these three exonuclease motifs, TREX1 has a highly 
hydrophobic carboxyl-terminal region which is predicted to form a 
transmembrane helix.6,18 Deletion mutagenesis has demonstrated 
that this region is important in intracellular localization but has no 
role in the catalytic function.2,6 The TREX1 protein also contains a 
proline-rich sequence (PPII helix).17,18 This motif has been reported 
to play a crucial role in protein-protein interactions, specifically 
with Src homology 3, WW and EVH1 domains.19 The structure of 
TREX1 indicates that the PPII helix is surface exposed and available 
for protein interactions.17,18 This has been hypothesized to account 
for the interaction of TREX1 with the SET complex17 (see below).
TREX1 Functions
Elucidation of the definitive in vivo function of TREX1 has 
proved problematic. TREX1 is an autonomous non-processive 3'–5' 
DNA-specific exonuclease with a preference for ssDNA or mispaired 
3' termini.12,13,20,21 Further analysis has suggested that, unusual for 
an exonuclease, TREX1 has a significant preference for particular 
DNA sequences and that this correlates with exonuclease activity.18 
This exonuclease function, in addition to slight homology with 
known editing enzymes, suggests that it may serve a DNA-editing 
role in DNA replication or gap filling during DNA repair. However, 
this has not been borne out by an increase in spontaneous muta-
tion rate or a higher cancer incidence in the Trex1 knockout mouse 
as would have been predicted if TREX1 served an obligatory role 
of editing mismatched 3' termini generated during DNA repair 
or DNA replication. Instead, the Trex1 knockout mouse displayed 
an autoimmune-like inflammatory myocarditis leading to a dilated 
cardiomyopathy and a dramatically reduced lifespan.22
Another role for TREX1 has been suggested by its association 
with the SET complex.23 This protein complex is involved in 
granzyme A-mediated cell death, a caspase-independent pathway 
which involves ssDNA damage. The killer lymphocyte associated 
protease, granzyme A, causes mitochondrial damage and superoxide 
generation that induces nuclear translocation of the SET complex. 
It then cleaves the NM23-H1 inhibitor, SET, freeing NM23-H1 to 
make a ssDNA cut (introduces a DNA nick) that is then extended 
by TREX1. Cells with silenced TREX1 are relatively resistant to 
apoptotic cell death but remain sensitive to the caspase-activating 
granzyme B.23
A role for TREX1 in cell homeostasis has recently been described 
by Yang and colleagues.24 They demonstrated that TREX1 defi-
ciency results in constitutive activation of the ATM-dependent 
DNA damage checkpoint. This results in impaired G1/S transition 
in Trex1-deficient cells. Additionally, a 60–65 bp ssDNA species 
accumulates in the cytoplasm. Importantly, similar phenotypic 
observations were obtained from both Trex1-deficient mouse cells as 
well as from patient cells homozygous for a non-functional mutant 
form of the protein. These roles of TREX1 have been postulated to 
be critical in controlling autoimmunity24,25 and will be discussed 
later.
TREX1 versus TREX2
TREX1 has a homologue, TREX2, which has ~40% amino acid 
sequence identity with TREX1.13,26 TREX2 is also an autonomous 
DNA 3'–5' exonuclease,13,26 important for cell proliferation.26 
TREX2 lacks the ~75 amino acid carboxyl-terminal hydrophobic 
domain found in TREX1. This region is responsible for intracel-
lular localization and contains the non-repetitive proline-rich region 
which plays a crucial role in protein-protein interactions. TREX2 
contains a conserved DNA binding loop positioned adjacent to the 
active site that has a sequence distinct from the corresponding loop 
in the TREX1 enzyme. These differences suggest non-overlapping 
physiological roles for these proteins.
Figure 1. Schematic diagram of the TREX1 protein structure with sites of mutations associated with human disease. Numbers for each mutation correspond 
with those listed in Table 1. Regions I, II and III represent the exonuclease domains (Exo I–III). Region P represents the polyproline II helix (PPII). Region TMD 
represents the putative transmembrane domain.
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Aicardi-Goutières Syndrome
In 1984, the autosomal recessive Aicardi-Goutières syndrome 
(AGS)(OMIM 225750) was first described in eight children from 
five unrelated families who developed progressive encephalopathy of 
early onset, brain atrophy, demyelination, basal ganglia calcifications 
and chronic cerebrospinal fluid (CSF) lymphocytosis.27 These clin-
ical findings mimic those observed with intrauterine infections but 
evaluation for an infectious etiology was negative. Affected children 
typically present before 4 months of age with failure to progress in 
motor and social skills while one-third of cases present later, between 
4 and 12 months of age, with loss of previously acquired motor and 
mental skills.28 Neurological manifestations also include spasticity 
and an acquired microcephaly. Extra-neurological features observed 
in a subset of patients include hepatosplenomegaly, anemia, throm-
bocytopenia, elevated liver transaminases and chilblains (ulcerating 
lesions on fingers, toes or ear lobes).28 Due to the similarity between 
AGS and intrauterine infection, levels of interferon α (IFNα) were 
measured and found to be elevated in the CSF of affected infants.29
Two other familial diseases, the microcephaly and intracranial 
calcification syndrome (MICS)30,31 and Cree Indian encephalitis,32 
which were initially described as separate disorders, have consider-
able overlap with AGS. All three are inherited as autosomal recessive 
diseases, can have increased levels of IFNα in the CSF, and manifest 
various extra-neurological findings such as hepatosplenomegaly, 
thrombocytopenia, elevated liver transaminases and chilblains.33,34 
Furthermore, Cree encephalitis has been found to be allelic with 
AGS.3,34 Thus, AGS, MICS and Cree encephalitis appear to repre-
sent the same disorder.
Several cases in the literature have also reported an overlap 
between AGS and infantile systemic lupus erythematosus (SLE).35-37 
In addition to findings compatible with the diagnosis of AGS, 
the affected children had autoantibodies typically found in lupus 
with antigenic specificity for cardiolipin, ssDNA, dsDNA and 
RNA-protein complexes. Notably, neuro-lupus has also been asso-
ciated with increased levels of IFNα in the CSF despite being a 
non-infectious disorder.38
The recent elucidation of the genetic basis for AGS provides a ratio-
nale for its clinical diversity. TREX1 mutations were first demonstrated 
to cause AGS by Crow et al. (AGS1, OMIM 225750).3 Functional 
characterization of only a few AGS associated TREX1 mutations have 
been performed3,5,13 (see Table 1); however, in the recessive mutations 
examined, a defect in exonuclease activity was demonstrated. This is 
further supported by Yang et al., who have demonstrated the presence 
of ssDNA in Trex1-null cells, findings also seen in AGS patient cells 
carrying homozygous mutations in TREX1.24
Although AGS is classically inherited in an autosomal recessive 
manner, there is an isolated report of an individual with an autosomal 
dominant form of the disease caused by a TREX1 mutation (AGS5; 
OMIM 610905).5 This individual possessed a D200N mutation 
which, on functional analysis, demonstrated close to normal levels of 
exonuclease activity. Although the mechanism of action remains to 
be established, it is proposed that this mutant alters the specificity of 
TREX1 or interferes with protein-protein interactions.
In addition to mutations in TREX1, mutations in three other 
genes [RNASEH2A (AGS4, OMIM 606034); RNASEH2B (AGS2, 
OMIM 610326); RNASEH2C (AGS3, OMIM 610330)] have 
been reported to cause AGS.39 RNase H2 is the principal source of 
ribonuclease activity in the cell,40,41 however, the mechanism through 
which a reduction in ribonuclease activity leads to disease remains 
speculative. Increased amounts of RNA-DNA hybrids stimulating 
an innate immune response with overproduction of IFNα have been 
hypothesized. In addition to these four causative genes, additional 
genes responsible for AGS are suggested by a cohort of affected indi-
viduals in whom mutations have not been identified.42
Analysis of a large cohort of AGS has revealed genotype:pheno- 
type correlations in the disease.42 For instance, individuals with 
TREX1 mutations tend to present at birth while individuals with 
mutations in RNASEH2B present later. AGS caused by RNASEH2B 
mutations also seems to have a milder phenotype with a lower 
mortality and relatively preserved intellectual function.42
Familial Chilblain Lupus
Familial chilblain lupus (FCL, OMIM 610448) is a rare cutaneous 
form of SLE. It is an autosomal dominant disease in which affected 
members present in early childhood with painful bluish-red inflam-
matory cutaneous lesions, typically on fingers, toes, ear helices, nose 
and cheeks. These lesions worsen with cold or wet exposure. They 
usually heal without scarring but may ulcerate leading to atrophic 
and hypopigmented skin and, in severe cases, to destruction of inter-
phalangeal joints and distal toes.4,5,43 Some affected individuals also 
have antinuclear antibodies and immune complexes.4,5,43 Progression 
to SLE is documented in 18% of individuals with chilblain lupus44 
but has not yet been described in individuals with FCL.
A SNP-based genome-wide linkage analysis mapped FCL to 
chromosome 3p and a subsequent haplotype analysis narrowed 
the locus to 3p21-14, an area that includes the gene for TREX1.4 
Although FCL is not associated with neurological pathology, there is 
some overlap with AGS in which some affected individuals develop 
chilblains and autoantibodies. Hence, TREX1 was considered a plau-
sible candidate gene and sequencing of affected individuals revealed 
several mutations.
Rice et al.5 reported a family with compound heterozygous 
mutations in three siblings (c.375dupT/F17S), though the disease 
segregated with only the c.375dupT mutation which was assumed 
to be inherited from the unstudied affected father. The c.375dupT 
mutation resulted in a truncated protein missing the last 188 amino 
acids, which would be predicted to be functionally significant. The 
mother carrying the F17S mutation was unaffected. This change is 
assumed to be a rare polymorphism. Exonuclease assays on lympho-
blastoid cell lines derived from the affected individuals demonstrate 
decreased enzymatic activity.5
Lee-Kirsch et al.43 described a heterozygous mutation (D18N) in 
a family with FCL. Functional analysis of this mutation revealed a 
loss of exonuclease function. Further analysis demonstrated reduced 
sensitivity to granzyme A-mediated cell death in patient-derived 
lymphoblastoid cell lines.
Retinal Vasculopathy and Cerebral Leukodystrophy
Cerebroretinal Vasculopathy (CRV) is an inherited disorder first 
described by Grand et al., in 1988.45 It begins in middle age with 
predominant central nervous system, especially retinal, involvement. 
Study of eight patients spanning three generations in the initial 
pedigree showed 100% penetrance with an autosomal dominant 
mode of inheritance. The disease manifestations begin during the 
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fourth or fifth decade and there is 100% mortality over a 5 to 10 
year period secondary to progressive neurological decline. Typical 
ophthalmologic findings on retinal fluorescein angiograms are capil-
lary dropouts, particularly in the macular region, leading to loss of 
central vision, prominent juxta-foveolar capillary obliteration and 
telangiectasias. Neurological manifestations commonly observed 
were transient ischemic attacks and strokes with motor and sensory 
loss, cognitive dysfunction, headaches, personality disorders, depres-
sion and anxiety. CT scans often show mass lesions with displacement 
of the surrounding structures and central contrast enhancement 
commonly in the frontoparietal region. Histopathology demon-
strates coagulative necrosis secondary to an obliterative vasculopathy 
and minimal inflammatory infiltrate (“as if the brain had been radi-
ated”). Autopsies demonstrate involvement of pons, cerebellum and 
basal ganglia in addition to the frontoparietal region.45 The CRV 
family has now been followed for over two decades (Atkinson JP, 
unpublished data). Hepatic and renal findings are not as clinically 
prominent as those seen in the nervous system but noteworthy 
from a clinical point of view in about one-third. Elevation of liver 
alkaline phosphatase is common and at autopsy, nodular regenera-
tive hyperplasia is found. Renal dysfunction of a glomerular origin 
with proteinuria and elevation of creatinine is also observed. Renal 
histopathology is most suggestive of accelerated arteriolonephroscle-
rosis. Small vessel type gastrointestinal bleeding is also seen. Taken 
together, these data implicate small vessel  vasculopathy leading to 
premature infarction and necrosis of the tissue.
A smaller family of Ashkenazi Jewish ancestry was next reported, 
in which the affected individuals had evidence of retinal vascul-
opathy on fluorescein angiograms and periventricular white matter 
lesions on brain MRI.46 No follow-up on this family was possible. 
Table 1 TREX1 mutations found in human disease
# Nucleotide change Amino acid change Exonuclease Function Intracellular Localization Disease Segregation Reference
1 520→A D18N Decreased NT FCL Het 43
2 58_59insG E20fs NT NT AGS Hom 3
3 212_2l3dupTG A72fs NT NT AGS Hom 42
4 341G→A R114H Decreased Perinuclear AGS Hom 2, 3
4 341G→A R114H Decreased Perinuclear SLE Het 2, 6
5 365T→C V122A NT NT AGS Hom 42
6 366_368dupGGC Al24ins NT NT AGS Hom 42
7 375dupT G126fs Decreased NT FCL Het 5
8 393_408dup E137fs NT NT AGS Hom 42
9 397delC L133fs NT NT AGS Hom 42
10 473C→T A158V NT NT SLE Het 6
11 490C→T R164X NT NT AGS Hom 3
12 500delG S167fs NT NT AGS Hom 42
13 598G→A D200N Normal NT AGS Het 5
14 600_60linsGAT D201ins Decreased NT AGS Comp het, R114H 3, 17
15 602T→A V201D Decreased NT AGS Hom 3, 17
16 609_662dup A203ins NT NT AGS Hom 42
17 625_628dupCAGT W210fs NT NT AGS Hom 42
18 634delC P212fs NT Cytoplasm SLE Het 6
19 703_704insG V235fs Normal Nucleus/Cytoplasm RVCL Het 2
20 706_707insA T236fs Normal Nucleus/Cytoplasm RVCL Het 2
21 679G→A G227S NT NT SLE Comp het, A247P? 6
22 720G→C R240S NT NT SLE Het 6
23 739G→C A247P NT NT SLE Comp het, G227S? 6
24 742_745dupGTCA T249fs NT Nucleus/Cytoplasm RVCL Het 2
25 812_8l3insAA P272fs Normal Nucleus SLE Het 6
26 850_851insA R284fs NT NT RVCL Het 2
27 857_858insG R287fs NT Nucleus/Cytoplasm RVCL Het 2
28 868_885del P290del NT NT AGS Hom 42
29 869C→T P290L NT NT SLE Het 6
30 907A→C T303P NT NT AGS Hom 42
31 914A→G Y305C NT NT SLE Het 6
32 917G→C G306A NT NT SLE Het 6
33 979delC 3' UTR NT NT SLE Het 6
Numbers correspond to those shown in Figure 1. NT: Not tested.
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However, in the original report45 there was also a patient of 
Ashkenazi Jewish origin with probable CRV whose disease has 
now been confirmed genetically.2 In 1999 and 2000, Weil et al.,47 
and Niedermayer et al.,48 respectively reported two other families 
thought to have CRV.
In 1990, Storimans et al. published a preliminary report describing 
Hereditary Vascular Retinopathy (HVR), a syndrome of retinal 
vasculopathy, migraines and Raynaud’s phenomena in a Dutch 
kindred.49 It was further described by Terwindt et al., in 1998.50 As 
initially reported, these patients did not appear to have pseudotu-
mors, renal dysfunction or shortened life expectancy similar to that 
seen in CRV patients. Furthermore, the visual acuity in these patients 
was largely preserved due to predominant peripheral retinal involve-
ment.50 However, further follow-up indicates that the clinical course 
is similar to the CRV and HERNS kindreds (see below; from Arn 
MJM van den Maagdenberg to JPA, personal communication).
In 1997, Jen et al., described a Chinese American family with 
11 affected members spanning three generations who manifested 
a CRV-like illness.51 This group named the disease Hereditary 
Endotheliopathy with Retinopathy, Nephropathy and Stroke 
(HERNS). Ultrastructural studies showed distinctive multilami-
nated vascular basement membrane in the brain and other tissues, 
including the kidney, gastrointestinal tract and skin. Genetic analysis 
ruled out linkage to the cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy (CADASIL) locus 
on chromosome 19.51
A whole genome screen in the extended Dutch family found 
probable linkage to 3p21.1-p21.3.1 Genetic analysis of patients 
from the CRV and HERNS kindreds demonstrated linkage to the 
same region. In 2005, Cohn et al., reported a family diagnosed with 
HERNS and prominent peripheral retinal involvement who also 
mapped to 3p21.1-p21.3.52 In 2007, CRV, HERNS and HVR were 
grouped together as Retinal Vasculopathy 
with Cerebral Leukodystrophy (RVCL, 
OMIM 192315) and the causative gene 
mutations were identified as carboxyl-
terminus frame shifts in TREX1.2 These 
mutant TREX1 forms (lacking their 
native carboxyl-termini), no longer 
localize to their usual perinuclear site.2 
Instead, they are now apparently capable 
of freely diffusing throughout the cell 
(Fig. 2C and corresponding intensity 
profiles D). Their distribution profile 
is indistinguishable from that of the 
fluorescent protein alone (Fig. 2A). 
Importantly, the exonuclease activity 
of these proteins is fully preserved. In 
contrast, fluorescent protein-tagged wild 
type TREX1 or TREX1 with deficient 
enzymatic activity are concentrated 
in the expected perinuclear space and 
are not detectable in the cytoplasm or 
nucleus (Fig. 2B).
A recent report by Winkler et 
al., details a familial disease they call 
Hereditary Systemic Angiopathy (HSA) 
which bears a remarkable resemblance to RVCL.53 The affected 
individuals present in the fourth to fifth decade with visual 
disturbances, migraine-like headaches, and neurological symptoms 
including seizures, motor paresis and cognitive decline. As the 
disease progresses, some develop renal and/or hepatic dysfunction. 
Furthermore, the pathologic findings correlate with those seen in 
RVCL. Although the authors had included CRV, HVR and HERNS 
in their differential diagnosis as separate entities, it is now clear that 
all three represent the spectrum encompassing RVCL and HSA 
would also seem to fall within that spectrum.
Systemic Lupus Erythematosus and Sjogren’s Syndrome
Systemic Lupus Erythematosus (SLE) (OMIM152700) and 
Sjögren’s syndrome (SS) (OMIM 270150) are prototypes of auto-
immune diseases because of the generation of a wide array of 
autoantibodies. SLE is clinically very heterogeneous and linkage 
studies and candidate gene studies have suggested many genes are 
involved in its pathogenesis (Table 1).54,55
As with AGS, SLE and SS are notable for the generation of anti-
nuclear antibodies and an IFNα activation signature. Rice et al. 
reported that at least one parent of a patient with AGS had SLE.5 
As a result of these similarities and the autoimmune phenotype of 
the Trex1 knockout mouse, Lee-Kirsch et al. sequenced the coding 
regions of TREX1 in lupus cohorts from the United Kingdom, 
Germany and Finland and discovered mutations in ~3% of indi-
viduals with SLE.6 Subsequent work also demonstrated TREX1 
mutations in individuals with SS.6
Mutations in SLE were seen throughout the TREX1 gene. 
Although functional analysis of the missense changes was not 
performed, at least one of the mutants described in SLE had been 
previously reported in AGS, R114H. Functional assessment of this 
mutant demonstrated decreased exonuclease activity, establishing 
Figure 2. Functional consequences of TREX1 mutations associated with RVCL. Confocal microscopy of 
HEK293T cells showing transiently expressed yellow fluorescent protein (eYFP)-tagged TREX1 proteins 
(green), TOPRO3 staining of nuclei (red), and the overlay for eYFP alone (A), wild-type TREX1 (B), and 
the CRV mutant form of TREX1 (C) as well as the corresponding intensity profile for each across region of 
drawn arrow (D).
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that at least some of the SLE mutants affect enzymatic function.36 
Other missense mutants, however, lie outside the catalytic domain 
and their functional significance remains unclear.6
Two frameshift mutations were also observed in SLE. Analogous 
to the mutations reported in RVCL, these mutations would not be 
predicted to disrupt enzymatic function. Functional analysis of one 
of these mutants, D272fs, failed to show any major enzymatic defi-
ciency; however, as with all mutations seen in RVCL, the frameshift 
mutations in SLE also altered subcellular localization. Interestingly, 
the two mutants observed in SLE had different intracellular distribu-
tions: the P212fs mutant distributed throughout the cytoplasm in 
endosomal vesicles while the D272fs mutant was almost exclusively 
localized within the nucleus, possibly in association with subnuclear 
organelles.6
In a recent study by Hur et al., although no conclusive association 
between TREX1 polymorphisms and SLE was demonstrated, certain 
TREX1 polymorphisms were protective against the development of 
autoantibodies.56
Discussion
This review has described four independent conditions found 
to have a common underlying etiology through mutations in the 
major mammalian autonomous 3'–5' exonuclease TREX1. Although 
mutations in TREX1 are connected to all four conditions, there are 
differences with respect to the functional changes which allow some 
genotype:phenotype correlations to be defined (Table 2).
Homozygous TREX1 mutations cause the typical autosomal reces-
sive form of AGS. Where functional analysis has been performed, 
these mutations result in decreased exonuclease function.3,5,17 
Only one documented case of autosomal dominant AGS has been 
described in the literature. Although the reported mutation does not 
alter exonuclease activity in vitro, it may be non-functional in vivo.5
FCL is associated with heterozygous mutations in TREX1. In all 
individuals examined these mutations result in reduced exonuclease 
activity.5,43 Some heterozygous parents of children with AGS have 
been reported to present with chilblains following cold exposure.5 
Although a much milder condition than AGS, FCL has sufficient 
phenotypic overlap (chilblain-like lesions and antinuclear antibodies) 
to suggest that the difference in these diseases may be a gene dosage 
effect. Therefore it appears that a partial loss of exonuclease activity 
is sufficient to cause FCL
RVCL is also associated with heterozygous mutations in TREX1. 
In contrast to the heterozygous mutations characterizing FCL, all 
the mutations described are in the carboxyl-terminus of TREX1 
and disrupt the predicted transmembrane domain.6,18 They do 
not diminish the enzymatic function of TREX1 but alter its intra- 
cellular localization.2 We speculate that the phenotype seen in RVCL 
is due to loss of the carboxyl-terminus which results in dissemination 
of TREX1 throughout the cell. We hypothesize that this leads to a 
detrimental gain-of-function phenotype. Alternatively, the mutations 
could just result in insufficient quantities of TREX1 in the correct 
location to fulfill its physiological role. How the latter explanation 
would fit with the phenotypic differences seen between RVCL and 
FCL is unclear.
Heterozygous mutations in TREX1 have also been identified in a 
small number of SLE patients. Unlike the mutations in FCL which 
disrupt exonuclease function and RVCL which disrupt intracellular 
localization, the mutations observed in SLE are diverse. Some muta-
tions disrupt exonuclease activity, others result in altered intracellular 
localization, and many are of unknown significance. SLE is a complex 
clinical disease and heterozygous mutations in TREX1 appear to 
account for only ~3% of cases.6 Detailed phenotypic examination of 
these individuals may result in a clearer understanding of the differ-
ences among RVCL, AGS and FCL.
These conditions also provide a window into a better under-
standing of the in vivo roles of TREX1. In the 10 years since TREX1 
was discovered, there has been much speculation on the cellular 
function of this enzyme. Based on its involvement in these human 
diseases and from knockout animal studies, it seems that TREX1 
does not have a requisite role in DNA repair. In contrast, it appears 
to be involved in the regulation of immunity through several non-
mutually exclusive pathways.
Yang et al., have recently demonstrated that TREX1-deficient cells 
accumulate ~60 bp ssDNA species in the cytoplasm.24 Such DNA 
intermediates are not exclusively generated during DNA replication. 
For example, DNA viruses and retroviruses are additional sources of 
DNA species that could accumulate if a degrading enzyme is lacking. 
In the absence of TREX1, the DNA intermediates required for the 
viral replication cycle could accumulate and become immunostimu-
latory. A similar scenario applies to active endogeneous retroviruses 
(and retrotransposons) residing in the human genome.25
Cell surveillance for viral DNA and RNA is in the form of 
Toll-like receptors, some of which reside in the cytoplasm.57 Under 
normal physiological conditions host DNA is sequestered from these 
receptors in the nucleus or mitochondria. It is possible that the cyto-
plasmic ssDNA plays a pathogenic role by mimicking viral DNA 
and stimulating these receptors. This will result in the production of 
antiviral cytokines including IFNα.
It is intriguing that both SLE and AGS are associated with high 
levels of IFNα. SLE has long been associated with high serum 
IFNα levels58 and these levels correlate with disease activity and 
severity.58-60 Evidence that the raised IFNα levels may be important 
in disease pathogenesis comes from individuals treated with IFNα 
for malignancies and chronic hepatitis C who have been seen to 
develop autoimmune diseases including SLE.61,62 Mouse models of 
SLE also lend weight to a pathogenic role for IFNα. Administration 
of IFNα, either exogenously,63,64 through an adenovirus vector,65 
or by injection of IFNα-inducing agents66 in mouse models of 
lupus have demonstrated increased severity of disease. Additionally, 
some lupus-prone mice lacking the Type I interferon receptor have a 
milder disease phenotype.67,68 A role for IFNα in the pathogenesis 
of AGS is suggested by the reproduction of the neuropathology in 
transgenic mice with astrocytes chronically producing IFNα who 
develop a progressive inflammatory encephalopathy, calcifications 
and neurodegeneration.69
Although no studies have examined IFNα in RVCL, several pieces 
of evidence may suggest such an association. Although distinct from 
the retinopathy of RVCL, there is a retinopathy associated with inter-
feron that is characterized by cotton wool spots, retinal hemorrhages 
and microaneurysms.70-74 Migraine and Raynaud’s phenomenon 
are also side-effects of IFNα treatment and are seen in RVCL. If the 
pathogenic role of IFNα in RVCL can be confirmed, then this would 
at last provide some hope for a condition which currently has a grim 
prognosis. Chloroquine and glucocorticoids have been used in SLE 
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Table 2 Clinical, pathological and laboratory features of diseases associated with TREX1 mutations
*One autosomal dominant case reported;4 ANA, antinuclear antibodies; APLS, antiphospholipid; CSF, cerebrospinal fluid; GI, gastrointestinal.
and inhibit IFNα production75 and the IFN signature76 respectively. 
Humanized monoclonal anti-IFNα antibodies77 and soluble IFNα 
receptors78 may also become therapeutic options. However, further 
investigation is required to confirm a pathogenic role for IFNα in 
RVCL as IFNα may not be the only link between TREX1 mutations 
and immunity.
Yang et al. also demonstrated that Trex1-deficient cells had consti-
tutive activation of the ATM-dependent DNA-damage checkpoint 
resulting in impaired G1/S transition.
24 This has been hypothesized 
to impair T-lymphocyte development which may reduce their 
ability to regulate self tolerance.25 TREX1 has also been shown to 
be involved in granzyme A-mediated cell death. Granzyme A is 
released by cytotoxic T-cells and NK-cells. It has been demonstrated 
that granzyme A-mediated cell death is impaired in FCL43 which 
may lead to the retention of autoreactive lymphocytes resulting in 
disease.
Thus, the last two years have seen the remarkable discovery 
of mutations in one gene, TREX1, which are responsible for four 
distinct clinical diseases. They have, however, areas of clinical and 
genetic overlap which point to a common pathological mecha-
nism. Further definition of the physiological and pathological role 
of TREX1 will hopefully lead to treatment advances for all these 
conditions.
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